Eterna Therapeutics
ERNA
$1.98
Share price
12.50%
Change (1 day)
-36.13%
Change (1 year)
Categories
Eterna Therapeutics (ERNA) - P/B ratio
P/B ratio as of May 2024 : 4.26
According to Eterna Therapeutics's latest financial reports the company has a price-to-book ratio of 4.26.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Eterna Therapeutics - P/B ratio (from 2021 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 4.35 | 218.94% |
| 2022-12-31 | 1.36 | -83.98% |
| 2021-12-31 | 8.51 | |
| 2020-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 1.51 | -64.70% | 🇫🇷 France |
 Baxter BAX | 2.28 | -46.47% | 🇺🇸 USA |
 Omeros Corporation OMER | -15.5 | -463.27% | 🇺🇸 USA |
 Geron GERN | 9.40 | 120.46% | 🇺🇸 USA |
 Genetic Technologies GENE | 3.23 | -24.25% | 🇦🇺 Australia |
 Teva Pharmaceutical Industries TEVA | 1.96 | -54.04% | 🇮🇱 Israel |
 Bio-Techne TECH | 6.19 | 45.10% | 🇺🇸 USA |